Adjunctive GM-CSF therapy enhances host defense against systemic <i>Candida auris</i> infection in immunosuppressed mice.

ABSTRACT:

Introduction

Candida auris is an emerging, multidrug-resistant fungal pathogen associated with high mortality in immunocompromised individuals. Resistance to current antifungal drugs emphasizes the need for new therapeutic approaches. We investigated granulocyte-macrophage colony-stimulating factor (GM-CSF) as a standalone immunotherapy and in combination with a sub-therapeutic dose of micafungin in an immunosuppressed mouse model of systemic C. auris infection.

Methods

Immunosuppressed ICR CD-1 mice (4-6 weeks old) were infected with C. auris and treated daily via intraperitoneal injection with PBS (placebo), murine GM-CSF (0.2 or 2 μg), micafungin, or both. Treatments began 24 h post-infection and continued through day 4 (GM-CSF) or day 7 (micafungin).

SUBMITTER: Mattos EC 

PROVIDER: S-EPMC12862068 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature